Cardiac Metastasis Of Thyroid Cancer

Anaplastic thyroid carcinomas are very aggressive cancers and metastasize frequently to the lungs and pleura. The cardiac metastases of thyroid cancers are rare. The diagnosis before the death is rare. We present a case of anaplastic thyroid carcinoma with metastatic involvement of the heart. It was presented with atrial fibrillation. The echocardiography demonstrated a solid mass in interventricular septum. One week later the patient died of heart failure. We call attention of clinicians that during the follow up of thyroid cancer such arrythmias may be the harbinger of a cardiac metastasis

Primary Breast Lymphoma Treated With R-Chop Chemotherapy

Primary breast lymphoma is rare disease which is treated with surgery, radiotherapy and chemoterapy. There is little experience of rituximab treatment is in breast lymphoma. Here we pres-ent a case of primary breast lymhoma treated with rituximab and chemotherapy combination. A 58-year-old woman referred for left breast mass. Radiologic imaging showed a mass of 4 cm in diameter. Pathologic examination of excisional biopsy specimen revealed Diffuse Large B Cell Lymphoma with CD20 positivity. The patient was stage IE (Ann Arbor). Mastectomy, lumpectomy or axil-lary dissection were not performed. Six courses of R-CHOP (CHOP plus rituximab) chemotherapy and radiotherapy were given. The complete response was obtained. The patient has been followed for 36 months with no evidence of disease recurrence. This is one of the first cases treated with rituximab. She has been followed for more than 36 months without relapse

The Diagnosis Of Non Hodgkin Lymphoma In An Epidermodysplasia Verruciformis Patient

Epidermodysplasia verruciformis is a rare, multifactorial disorder. The disease has genetic and immunologic components. Many patients have impaired cell-mediated immunity. Although squamous cell cancers may develop in EV patients, the association with other hematological or solid malignancies and EV is reported in a few studies. In this report, a case of EV with primary mediastinal large B-cell lymphoma is presented. A 20-year-old man with a five years history of red-brown macular lesions was admitted to our hospital. The skin biopsy revealed epidermodysplasia verruciformis. Persistent cough started during the hospitalization. On the chest X-ray, mediastinal enlargement was determined. Thoracic computed tomography demonstrated a mediastinal mass of 6 cm in diameter. Diffuse, large B-cell lymphoma was diagnosed. The chemotherapy (R-CHOP regiment) and involved field radiotherapy were administered. Complete response was achieved after the combined treatment modality. He is lymphoma- free for 18 months follow-up. Epidermodysplasia verruciformis is frequently seen in immunosuppressive patients and many accompany infections with type human papilloma virus subtypes such as 5 and 8. These human papilloma virus subtypes that have oncogenic properties may trigger lymphomagenesis. In addition, lymphomas are seen more frequently in immunosuppressive patients than healthy persons. We conclude that there may be a predisposition to lymphoma development in epidermodysplasia verruciformis patients

Efficacy and safety profile of COVID-19 vaccine in cancer patients: A prospective, multicenter cohort study

Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov) Plain language summary Cancer patients are at high risk for infection with SARS-CoV-2 and of developing the associated disease, COVID-19, which therefore puts them in the priority group for vaccination. This study evaluated the efficacy and safety of CoronaVac, an inactivated virus vaccine, in cancer patients. The immune response rate, defined as seropositivity, was 85.2% in the cancer patient group and 97.5% in the control group. The levels of antibodies, which are blood markers of immune response to the vaccine, were also significantly lower in the patient group, especially in those older than 60 years and receiving chemotherapy. These results highlight the importance of determining the effective vaccine type and dose in cancer patients to protect them from COVID-19 without disrupting their cancer treatment.Oncological Clinical Research Association (ONKAD